发现了帕林德罗姆双PPARγ-GPR40抗原剂,用于治疗2型糖尿病
Ana Rodríguez-Luévano1, Julio C Almanza-Pérez2, Rolffy Ortiz-Andrade3
1Departamento de Posgrado en Biología Molecular, División de Biología Molecular, Institution Instituto Potosino de Investigación Científica y Tecnológica (IPICYT), S.L.P, San Luis Potosí, 78216, México.
ChemMedChem
|September 5, 2024
概括
这项研究引入了一种用于治疗2型糖尿病的新型帕林德罗姆化合物设计,同时向PPARγ和GPR40受体. 化合物2有效地激活这些目标而不会引起低血糖症,显示出糖尿病治疗的前景.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 2型糖尿病的管理需要针对关键代谢途径的新型治疗策略.
- 过氧体增殖器激活受体玛 (PPARγ) 和G蛋白结合受体40 (GPR40) 是葡萄糖平衡的关键标.
- 同时调节PPARγ和GPR40为改善血糖控制提供了一个潜在的方法.
研究的目的:
- 设计和合成针对PPARγ和GPR40受体的新型双重作用化合物.
- 评估一种帕林德罗姆化合物 (化合物2) 对2型糖尿病治疗的体外和体内疗效.
- 评估开发的化合物的安全性,特别是缺乏低血糖的情况.
主要方法:
- 多步化学合成的双双组合物.
- 在体外测试测量PPARγ,GPR40和GLUT-4在C2C12和RIN-m5f细胞中的mRNA表达.
- 评估胰岛素分泌和GLUT-4转位.
- 在正常血糖和非胰岛素依赖性糖尿病 (NIDDM) 鼠标模型中的体内研究.
- 分子动力学模拟用于分析受体相互作用.
主要成果:
- 化合物2表明PPARγ和GPR40.0的mRNA表达中度增加.
- 观察到显著的GLUT-4载体转移 (400%),与pioglitazone相比.
- 在糖尿病大鼠中,复合物2维持了基底血葡萄糖和中度胰岛素释放,没有降血糖.
- 分子动力学证实了与GPR40和PPARγ受体的持续相互作用.
结论:
- 帕林德罗姆设计是开发双PPARγ和GPR40激动剂的可行策略.
- 化合物2有效地激活了这两种受体,并增强了葡萄糖的吸收,而不会引起低血糖症.
- 这种双重作用的化合物显示出治疗2型糖尿病的治疗潜力.
相关概念视频
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
G Protein-coupled Receptors
11.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167


